KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) FCF Margin (2016 - 2025)

Historic FCF Margin for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Q3 2025 value amounting to 32.17%.

  • Supernus Pharmaceuticals' FCF Margin fell 625200.0% to 32.17% in Q3 2025 from the same period last year, while for Sep 2025 it was 10.38%, marking a year-over-year decrease of 160000.0%. This contributed to the annual value of 25.87% for FY2024, which is 76800.0% up from last year.
  • Supernus Pharmaceuticals' FCF Margin amounted to 32.17% in Q3 2025, which was down 625200.0% from 35.1% recorded in Q2 2025.
  • Supernus Pharmaceuticals' FCF Margin's 5-year high stood at 41.98% during Q2 2022, with a 5-year trough of 32.17% in Q3 2025.
  • Over the past 5 years, Supernus Pharmaceuticals' median FCF Margin value was 25.38% (recorded in 2024), while the average stood at 18.51%.
  • Per our database at Business Quant, Supernus Pharmaceuticals' FCF Margin surged by 351700bps in 2024 and then tumbled by -625200bps in 2025.
  • Over the past 5 years, Supernus Pharmaceuticals' FCF Margin (Quarter) stood at 30.66% in 2021, then plummeted by -46bps to 16.57% in 2022, then skyrocketed by 65bps to 27.38% in 2023, then fell by -7bps to 25.38% in 2024, then crashed by -227bps to 32.17% in 2025.
  • Its FCF Margin stands at 32.17% for Q3 2025, versus 35.1% for Q2 2025 and 20.21% for Q1 2025.